Compare Deere & Company (DE) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs DexCom, Inc. — how do they compare? Deere & Company trades at $652.58 (market cap $177.11B), while DexCom, Inc. trades at $84.38 (market cap $31.81B). The key difference: Deere & Company is far larger — about 5.6× DexCom, Inc.'s market cap, and Deere & Company pays a 0.99% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and DexCom, Inc. for 62 Days on average.
| DE | DXCM | |
|---|---|---|
Market Cap | $177.11B | $31.81B |
Volume | 1,206,308 | 2,861,821 |
Sector | Industrials | Health |
52-Week High | $709.48 | $92.34 |
52-Week Low | $439.11 | $54.84 |
Typical Hold Time | 75 Days | 62 Days |
Enterprise Value | $231.01B | $31.26B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $652.58, down 4.42% today, showing bearish technical signals with support at $643 and resistance at $658. The company maintains strong profitability with a 10.39% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Deere's AI initiatives and institutional buying interest, though revenue has declined from 2023 peaks.
Deere presents a mixed outlook with solid fundamentals and analyst support (43.48% buy rating, $731.20 target) but faces agricultural cycle headwinds and competitive pressures. The stock offers potential upside from AI-driven farming solutions but risks include cyclical demand volatility and high debt levels at 60.31% of assets.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
